Sangamo to put ‘substantially all’ assets for sale in bankruptcy, lines up Lilly and Astellas as buyers
Sangamo Therapeutics' bankruptcy filing and asset sale to Lilly and Astellas is making waves in the biotech industry.
Velocity
How fast coverage is spreading — measured hourly from article rate × source diversity. How this works →
📍 How it ended
Sangamo Therapeutics filed for Chapter 11 bankruptcy protection and planned to put substantially all assets for sale. Eli Lilly and Astellas emerged as buyers, with stalking horse sales set at $50 million for Lilly and up to $50 million for Astellas.
Epilogue added 6d ago, after coverage quieted.
The brief
Sangamo Therapeutics has filed for bankruptcy and plans to sell substantially all of its assets. The company has lined up Eli Lilly and Astellas as potential buyers. Lilly is set to acquire assets worth $50 million, with Astellas potentially acquiring assets worth up to $50 million.
Coverage emphasizes the strategic moves by Lilly and Astellas to acquire Sangamo's assets. Reports from FirstWord Pharma, The Business Journals, BioSpace, and Fierce Biotech highlight the bankruptcy filing and the asset sale process. Law360 and TradingView provide details on the Chapter 11 filing and the stalking horse sales.
What to watch next: The outcome of the asset sale process. Coverage does not yet specify the timeline for the completion of the sales or any regulatory approvals that may be required.
Synthesized by Archynetys from the headlines below under a strict no-invention contract. ✓ fact-checked: all claims supported by sources Updated 19d ago.
Quick answers
Why is Sangamo Therapeutics filing for bankruptcy?
Coverage does not yet specify the reasons behind Sangamo Therapeutics' bankruptcy filing.
What assets are Lilly and Astellas acquiring from Sangamo?
Coverage does not yet specify the exact assets being acquired by Lilly and Astellas from Sangamo.
What is the timeline for the completion of the asset sales?
Coverage does not yet specify the timeline for the completion of the asset sales.
Coverage (8)
- Sangamo Therapeutics, Inc. Filed for Bankruptcy marketscreener.com · 20d ago
- Lilly, Astellas bid on Sangamo's assets after bankruptcy filing FirstWord Pharma · 20d ago
- Sangamo Therapeutics files for bankruptcy as Lilly and Astellas split assets The Business Journals · 20d ago
- Sangamo Therapeutics Files for Chapter 11 Bankruptcy Protection citybiz · 20d ago
- Gene Therapy Developer Sangamo Hits Ch. 11 With Sale Plans Law360 · 20d ago
- Sangamo Therapeutics Sets Stalking Horse Sales: $50M to Eli Lilly, Up to $50M to Astellas TradingView · 20d ago
- UPDATE: Lilly, Astellas circle Sangamo assets as biotech files for bankruptcy BioSpace · 20d ago
- Sangamo to put ‘substantially all’ assets for sale in bankruptcy, lines up Lilly and Astellas as buyers Fierce Biotech · 20d ago
Topics
Related trends
A tiny GLP-1 implant is the latest bet to help patients maintain their weight loss
Novo Nordisk has entered into a partnership with Vivani to develop a long-acting semaglutide implant designed for weight management.
'We're paranoid.' As China biotech competition heats up, American drugmakers get more secretive
6 news sources are covering this Business story right now — Archynetys is tracking how fast it spreads.
Why AstraZeneca Crashed 6%, Leading Two Rivals, Including Pfizer, To Jump
4 news sources are covering this Business story right now — Archynetys is tracking how fast it spreads.
The First AI‑Designed Vaccine Has Been Tested in People. Here’s What Happened.
Clinical trials for the world's first AI-designed vaccine have entered human testing, marking a potential shift in medical development methodology.
Brain tumors: New vaccine offers patients hope for more time
6 news sources are covering this Health story right now — Archynetys is tracking how fast it spreads.
Victims of 23andMe data breach to get $47m payout, judge rules
A judge has approved a $47 million payout for victims of the 23andMe data breach.